(Q53624451)

English

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

0 references

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. (English)

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

R Gray

8

0 references

author name string

R D Gelber

1

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

B F Cole

2

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

A Goldhirsch

3

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

C Rose

4

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

B Fisher

5

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

C K Osborne

6

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

F Boccardo

7

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

N H Gordon

9

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

N O Bengtsson

10

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

P Sevelda

11

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

language of work or name

0 references

publication date

1 April 1996

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

347

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

1066-1071

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

9008

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality adjusted survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant hormonal chemotherapy in early breast cancer: early results from a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of radiotherapy in high-risk breast cancer patients: report from the Danish Breast Cancer Cooperative Group (DBCG 82) Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Utility approach to measuring health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Understanding adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2990277-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(96)90277-9

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/8602056

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53624451&oldid=1962205624"